Phase 1 Study to Assess the Safety, Tolerability, and Pha... | NCT02663687

NCT02663687

Status Module

Sponsor/Collaborators Module

Oversight Module

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Treatment 1- 4	Experimental	Treatment A: 9 Subjects will receive dose level I of SHP623 intravenously (IV). B: 9 Subjects will receive dose level I of SHP623 subcutaneously(SC).	Drug: Recombinant human C1 esterase inhibitor Drug: SHP623
Placebo	Placebo Comparator	3 Subjects will receive placebo for each cohort	Drug: Placebo

Name	Type	Description	Arm Group Labels	Other Names
Recombinant human C1 esterase inhibitor	Drug	Subjects will receive escalating doses I-IV as both IV and SC injections	Treatment 1- 4

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of Participants With Treatment-emergent Adverse Events (TEAEs ) Including Serious Adverse Events (SAEs)	An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. An AE was considered to be a TEAE in a specific treatment period of the study if the date and time of onset were after investigational product administration in that period and if it occurred less than equals to (<=) Day 28 and was both not present at the start of that period and was not a chronic condition that was part of the participant's medical history, or it was present at the start of that period or as part of the participant's medical history but the severity or frequency increased during that period <= Day 28. An SAE was defined as any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose.	From the start of study treatment up to 28 days after the last dose of the study treatment (up to 56 days)

Secondary Outcomes

Measure	Description	Time Frame
Maximum Observed Plasma Concentration (Cmax) of SHP623 Occurring at Time of Maximum Observed Concentration During a Dosing Interval (Tmax)	Cmax of SHP623 recombinant human C1 esterase inhibitor (rC1 INH) antigen at Tmax was calculated based on observed concentration-versus-time data. Cmax at Tmax of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Study Director	Takeda	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Clinical Pharmacology of Miami		Miami	Florida	33014	United States

References Module

No data available

No data is available for this block.

IPD Sharing Statement Module

No data available

No data is available for this block.

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Placebo	Participants received placebo matched to SHP623 intravenous (IV) and subcutaneous (SC) administration in 1:3 ratio for each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

Masking Info

Safety analysis set consisted of all participants who were administered at least 1 dose of investigational product.

Arm/Group Information

ID	Title	Description
BG000	Placebo	Participants received placebo matched to SHP623 intravenous and subcutaneous administration in 1:3 ratio for each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between intravenous (IV) and subcutaneous (SC) dosing in the following order: once as an IV dose and once as an SC dose.
BG001	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
BG002	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
BG003	3000 U SHP623	Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
BG004	5000 U SHP623	Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
BG005	Total	Total of all reporting groups

Units	Counts
Participants	BG00012 BG0019 BG0029 BG0039 BG0049 BG00548

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Continuous

Age was calculated as the difference between date of birth and date of informed consent, truncated to years.

Mean

Standard Deviation

Years

Title

Denominators

Categories

Any TEAE

Title	Measurements
	OG0008 OG0014 OG0023 OG003

Secondary

Maximum Observed Plasma Concentration (Cmax) of SHP623 Occurring at Time of Maximum Observed Concentration During a Dosing Interval (Tmax)

Cmax of SHP623 recombinant human C1 esterase inhibitor (rC1 INH) antigen at Tmax was calculated based on observed concentration-versus-time data. Cmax at Tmax of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.

Pharmacokinetic (PK) set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.

Posted

Mean

Standard Deviation

microgram per milliliter (mcg/ml)

Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.

ID	Title	Description
OG000	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG001	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG002

Secondary

Time of Maximum Plasma Concentration (Tmax) of SHP623 Sampled During a Dosing Interval

Tmax of SHP623 (rC1 INH) antigen was calculated based on observed concentration-versus-time data. Tmax of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.

PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.

Posted

Median

Full Range

hour (h)

Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.

ID	Title	Description
OG000	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG001	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG002	3000 U SHP623

Secondary

Terminal Half-life (t1/2) of SHP623

t1/2 is the time required for the concentration of the drug to reach half of its original value. t1/2 of SHP623 (rC1 INH) antigen for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group.

PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.

Posted

Median

Full Range

hour (h)

Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.

ID	Title	Description
OG000	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG001	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG002	3000 U SHP623	Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.

Secondary

Area Under the Plasma Concentration Curve From Time Zero to Infinity (AUC 0-inf) of SHP623

AUC 0-inf is the area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration. AUC 0-inf of SHP623 (rC1 INH) antigen was calculated from observed concentration-versus-time data. AUC 0-inf of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).

PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.

Posted

Mean

Standard Deviation

hr*mcg/ml

Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.

ID	Title	Description
OG000	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG001	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.

Secondary

Area Under the Plasma Concentration Curve From Time Zero to 168 Hours Postdose (AUC 0-168) of SHP623

AUC 0-168 is the area under the concentration curve over the interval from 0 to 168 hours after dosing of SHP623. AUC 0-168 of SHP623 (rC1 INH) was calculated based on observed concentration-versus-time data. AUC 0-168 of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).

PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.

Posted

Mean

Standard Deviation

hr*mcg/ml

Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.

ID	Title	Description
OG000	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG001	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.

Secondary

Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of SHP623

AUClast is the area under the curve from the time 0 to the last measurable concentration of SHP623 (rC1 INH), which was calculated from observed concentration-versus-time data. AUClast of SHP623 for both treatment period 1 (IV) and treatment period 2 (SC) was presented in the categories for each dosing group. The unit of measure is hour*microgram per milliliter (hr*mcg/ml).

PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.

Posted

Mean

Standard Deviation

hr*mcg/ml

Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.

ID	Title	Description
OG000	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG001	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.

Secondary

Total Body Clearance (CL) for Intravascular (IV) Administration of SHP623

CL is the total body clearance of SHP623 for IV administration. The unit of measurement is unit per hour*microgram per milliliter [U/(hr*mcg/ml)].

PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.

Posted

Mean

Standard Deviation

U/(hr*mcg/ml)

Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.

ID	Title	Description
OG000	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG001	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG002	3000 U SHP623	Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.

Secondary

Volume of Distribution Associated With the Terminal Slope (Vz) Following Intravenous (IV) Administration of SHP623

Vz is the volume of distribution associated with the terminal slope following IV administration. Vz was calculated for SHP 623 (rC1 INH) antigen from observed concentration-versus-time data. The unit of measure is unit per microgram per milliliter [U/(mcg/ml)].

PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.

Posted

Mean

Standard Deviation

U/(mcg/ml)

Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.

ID	Title	Description
OG000	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG001	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG002	3000 U SHP623

Secondary

Total Body Clearance for Extravascular Administration (CL/F) of SHP623 for Subcutaneous (SC) Administration

CL/F is the total body clearance for extravascular administration of SHP623 for SC administration divided by the fraction of dose absorbed. CL/F of SHP623 (rC1 INH) was calculated based on observed concentration-versus-time data. The unit of measure is unit per hour*microgram per milliliter [U/(hr*mcg/ml)].

PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.

Posted

Mean

Standard Deviation

U/(hr*mcg/ml)

Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.

ID	Title	Description
OG000	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG001	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and treatment period 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG002	3000 U SHP623

Secondary

Volume of Distribution Influenced by Fraction of Dose Absorbed (Vz/F) Following Extravascular Administration of SHP623

Vz/F is the volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed for subcutaneous (SC) administration. Vz/F of SHP623 (rC1 INH) were calculated from observed concentration-versus-time data. The unit of measure is unit per microgram per milliliter [U/(mcg/ml)].

PK set consisted of all participants in the safety analysis set for whom the primary PK data were considered sufficient and interpretable.

Posted

Mean

Standard Deviation

U/(mcg/ml)

Pre-dose, 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 216, 312, 648 hours post-dose.

ID	Title	Description
OG000	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG001	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 and 2 for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.
OG002	3000 U SHP623

Arm/Groups

ID	Title	Description	Deaths (At Risk)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Placebo	Participants received placebo matched to SHP623 intravenous (IV) and subcutaneous (SC) administration in 1:3 ratio for each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.	12	12	8	12
EG001	1000 U SHP623	Participants received 1000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.	9	9	4	9
EG002	2000 U SHP623	Participants received 2000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.	9	9	3	9
EG003	3000 U SHP623	Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.	9	9	8	9
EG004	5000 U SHP623	Participants received 5000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.	9	9	4	9

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Back pain	Musculoskeletal and connective tissue disorders	MedDRA 19.1	Non-systematic Assessment	EG0000 events0 affected12 at risk EG0010 events0 affected9 at risk EG0020 events0 affected9 at risk EG0031 events1 affected9 at risk EG0040 events0 affected9 at risk
Constipation	Gastrointestinal disorders	MedDRA 19.1	Non-systematic Assessment	EG0000 events0 affected12 at risk EG0010 events0 affected9 at risk EG0020 events0 affected9 at risk EG003
Diarrhoea	Gastrointestinal disorders	MedDRA 19.1	Non-systematic Assessment	EG0001 events1 affected12 at risk EG0010 events0 affected9 at risk EG0020 events0 affected9 at risk EG003
Dry mouth	Gastrointestinal disorders	MedDRA 19.1	Non-systematic Assessment	EG0000 events0 affected12 at risk EG0010 events0 affected9 at risk EG0020 events0 affected9 at risk EG003
Dyspepsia	Gastrointestinal disorders	MedDRA 19.1	Non-systematic Assessment	EG0000 events0 affected12 at risk EG0011 events1 affected9 at risk EG0020 events0 affected9 at risk EG003
Nausea	Gastrointestinal disorders	MedDRA 19.1	Non-systematic Assessment	EG0000 events0 affected12 at risk EG0010 events0 affected9 at risk EG0020 events0 affected9 at risk EG003
Injection site pain	General disorders	MedDRA 19.1	Non-systematic Assessment	EG0001 events1 affected12 at risk EG0010 events0 affected9 at risk EG0022 events2 affected9 at risk EG003
Liver function test abnormal	Investigations	MedDRA 19.1	Non-systematic Assessment	EG0001 events1 affected12 at risk EG0010 events0 affected9 at risk EG0020 events0 affected9 at risk EG003
Headache	Nervous system disorders	MedDRA 19.1	Non-systematic Assessment	EG0006 events5 affected12 at risk EG0013 events3 affected9 at risk EG0022 events2 affected9 at risk EG003
Somnolence	Nervous system disorders	MedDRA 19.1	Non-systematic Assessment	EG0001 events1 affected12 at risk EG0010 events0 affected9 at risk EG0020 events0 affected9 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	MedDRA 19.1	Non-systematic Assessment	EG0000 events0 affected12 at risk EG0010 events0 affected9 at risk EG0020 events0 affected9 at risk EG003
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	MedDRA 19.1	Non-systematic Assessment	EG0000 events0 affected12 at risk EG0011 events1 affected9 at risk EG0020 events0 affected9 at risk EG003
Dermatitis	Skin and subcutaneous tissue disorders	MedDRA 19.1	Non-systematic Assessment	EG0000 events0 affected12 at risk EG0010 events0 affected9 at risk EG0021 events1 affected9 at risk EG003
Dermatitis contact	Skin and subcutaneous tissue disorders	MedDRA 19.1	Non-systematic Assessment	EG0001 events1 affected12 at risk EG0010 events0 affected9 at risk EG0020 events0 affected9 at risk EG003

ID	Term
D054179	Angioedemas, Hereditary

Ancestor Terms

ID	Term
D000799	Angioedema
D014652	Vascular Diseases
D002318	Cardiovascular Diseases
D000081208	Hereditary Complement Deficiency Diseases
D000081207	Primary Immunodeficiency Diseases
D030342	Genetic Diseases, Inborn
D009358	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
D014581	Urticaria
D017445	Skin Diseases, Vascular
D012871	Skin Diseases
D017437	Skin and Connective Tissue Diseases
D006969	Hypersensitivity, Immediate
D006967	Hypersensitivity
D007154	Immune System Diseases
D007153	Immunologic Deficiency Syndromes

ID	Term
C571093	conestat alfa

Participants received 3000 unit (U) of SHP623 in each cohort during treatment period 1 (IV) and treatment period 2 (SC) for 28 days respectively with 28 days interval between IV and SC dosing in the following order: once as an IV dose and once as an SC dose.

EG0040 events0 affected9 at risk

EG0041 events1 affected9 at risk

EG0040 events0 affected9 at risk

EG0041 events1 affected9 at risk

EG0040 events0 affected9 at risk

Title	Measurements
	OG0004.248± 1.7445 OG00115.694± 4.2062 OG00216.318± 4.5612 OG00332.056± 8.7727

Title	Measurements
	OG00072.000(36.00 to 144.00) OG00136.000(24.00 to 72.00) OG00248.000(36.00 to 96.00) OG00348.000(36.00 to 96.00)

Title	Measurements
	OG00051.8(34.0 to 80.4) OG00149.8(42.4 to 65.9) OG00259.5(46.3 to 71.7) OG00351.8(35.8 to 63.3)

Title	Measurements
	OG000594.741± 101.0006 OG0011653.875± 318.0261 OG0022304.409± 590.0275 OG0034174.091± 854.5110

Title	Measurements
	OG000407.936± 149.3221 OG0011414.762± 328.9591 OG0021792.962± 488.0679 OG0033386.375± 790.1633

Title	Measurements
	OG000401.030± 147.1284 OG0011518.124± 341.5602 OG0022159.527± 599.1840 OG0034040.772± 845.6065